Although there has been an overall decline in HIV incidence in the United States in recent years, new HIV infections have been increasing among populations of men who have sex with men (MSM). Within this context, HIV pre-exposure prophylaxis (PrEP) holds considerable promise as a highly effective biomedical HIV prevention strategy. The effectiveness of PrEP, however, is dependent on treatment adherence, retention in care, and the continued use of condoms. Identifying and addressing factors that detract from these PrEP- relevant behaviors is therefore imperative for maximizing the HIV preventive benefits of PrEP. Hazardous alcohol consumption, and concurrent conditions such as substance use and depression, have been shown to adversely impact a variety of health behaviors, and although these concerns are prevalent among PrEP- prescribed MSM, little work has been conducted to investigate their role in PrEP treatment. The present study involves a two-phased approach designed to 1) gain a better understanding of the associations among alcohol use, concurrent substance use and depression, and PrEP-related behaviors among PrEP-prescribed MSM (UH2 phase); and 2) explore whether addressing hazardous drinking and concurrent conditions can potentially lead to improvements in MSM's PrEP-related behaviors (UH3 phase). The first phase of this research (UH2) will involve 1) up to five focus groups with PrEP-prescribed MSM to explore barriers to PrEP adherence, retention in PrEP-related care, and condom use; with an emphasis on alcohol consumption and concurrent conditions; 2) surveys with 120 PrEP-prescribed MSM to identify rates of, and associations among, PrEP adherence, condomless sex, hazardous drinking, and concurrent conditions; and 3) chart reviews of over 400 PrEP-prescribed MSM to ascertain clinically-identified rates of, and associations among, PrEP adherence, retention in PrEP-related care, sexually transmitted infections, hazardous drinking, and concurrent conditions. Building on this initial work, the second phase of this research (UH3) will entail a pilot randomized controlled trial in which 120 hazardous drinking, PrEP-prescribed MSM will be randomly assigned to receive either a tablet-based, alcohol-reduction brief intervention or treatment-as-usual. Participants assigned to the former condition for whom substance use- and/or depression-related concerns are identified will be provided with links to relevant resources. All trial participants will complete biomarker testing and self-report assessments at baseline, 3-months, and 6-months to assess the preliminary impact of the intervention on alcohol use, PrEP adherence, retention in care, and condomless sex. Feasibility and acceptability of the intervention will also be examined. Taken together, findings from both phases of this research will not only provide much needed insight into the possible impact of hazardous alcohol use and concurrent conditions on PrEP treatment, but they will also have the potential to guide future initiatives aimed at enhancing PrEP treatment effectiveness.

Public Health Relevance

Although HIV pre-exposure prophylaxis (PrEP) is an effective tool that can help prevent the acquisition of HIV, its effectiveness has been shown to be dependent on a number of key behaviors, including adherence to the treatment, attendance in follow-up care, and the continued use of condoms. This investigation, focused on men who have sex with men (MSM) who have been prescribed PrEP, will seek to 1) assess the extent to which hazardous alcohol consumption and concurrent conditions (i.e., substance use and depression) are linked to key PrEP-related behaviors; and 2) explore whether reducing hazardous alcohol consumption and addressing concurrent conditions can result in improvements in the enactment of key PrEP-related behaviors. Findings from this research will have a significant impact on public health, in that the knowledge to be gained can be used to guide the development of future initiatives aimed at enhancing PrEP treatment, which in turn could help reduce the rate of new HIV infections among MSM.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Exploratory/Developmental Cooperative Agreement Phase I (UH2)
Project #
5UH2AA026212-02
Application #
9564047
Study Section
Special Emphasis Panel (ZAA1)
Program Officer
Roach, Deidra
Project Start
2017-09-15
Project End
2019-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Centre for Addiction and Mental Health
Department
Type
DUNS #
207855271
City
Toronto
State
ON
Country
Canada
Zip Code
M5S2S1